Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.
about
Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infectionRoutine viral load monitoring versus standard care for reducing morbidity and mortality in adolescent and adult patients living with HIV on antiretroviral therapy (ART)Interventions for previously untreated patients with AIDS-associated Non-Hodgkin´s LymphomaIncreasing disparities between resource inputs and outcomes, as measured by certain health deliverables, in biomedical researchSystematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy.Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studiesLatent reservoirs of HIV: obstacles to the eradication of virusContinuing HIV therapy in the ICUAIDS-defining illnesses among patients with HIV in Singapore, 1985 to 2001: results from the Singapore HIV Observational Cohort Study (SHOCS)The epidemiological impact of antiretroviral use predicted by mathematical models: a review.Phenylethylthiazolylthiourea (PETT) non-nucleoside inhibitors of HIV-1 and HIV-2 reverse transcriptases. Structural and biochemical analysesBinding of the second generation non-nucleoside inhibitor S-1153 to HIV-1 reverse transcriptase involves extensive main chain hydrogen bondingSynthesis, X-ray Analysis, and Biological Evaluation of a New Class of Stereopure Lactam-Based HIV-1 Protease InhibitorsEfavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsCauses of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapyImpact of antiretroviral therapy on the incidence of tuberculosis: the Brazilian experience, 1995-2001Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-scoreStanding genetic variation and the evolution of drug resistance in HIVEpidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipientsHepatitis B virus infection in HIV-positive individuals in the UK collaborative HIV cohort (UK CHIC) studyImmuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in EuropeDevelopment and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D studyPre-ART levels of inflammation and coagulation markers are strong predictors of death in a South African cohort with advanced HIV diseaseEfavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individualsTuberculosis and HIV: a partnership against the most vulnerable.HIV-1 Genetic Variability and Clinical ImplicationsHIV/AIDS epidemiology, pathogenesis, prevention, and treatmentMorbidity and Mortality Patterns of Hospitalised Adult HIV/AIDS Patients in the Era of Highly Active Antiretroviral Therapy: A 4-year Retrospective Review from Zaria, Northern Nigeria.Life expectancy after HIV diagnosis based on data from the counseling center for behavioral diseases.Patient satisfaction with antiretroviral services at primary health-care facilities in the Free State, South Africa--a two-year study using four waves of cross-sectional data.Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.Highly active antiretroviral treatment and health related quality of life in South African adults with human immunodeficiency virus infection: A cross-sectional analytical study.Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania.Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis.Predictors of mortality in HIV-associated hospitalizations in Portugal: a hierarchical survival model.Inhibition of HIV-1 entry by extracts derived from traditional Chinese medicinal herbal plantsHepatic profile analyses of tipranavir in Phase II and III clinical trialsEffects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART studyMortality reduction associated with HIV/AIDS care and antiretroviral treatment in rural Malawi: evidence from registers, coffin sales and funeralsLow level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors.
P2860
Q24194805-D7A98BEE-7F5D-44E3-9B40-87D1D8A286EBQ24203980-7EB12D00-1A1E-4C63-8584-A802CEF0A636Q24240190-85AAC882-CE06-4750-8BA8-DAABA35992B4Q24289253-B2904C8C-48C7-4B26-A745-EFEC5B51A3E7Q24514773-4C619290-42C8-4B1A-BF85-3EB28FBBCCA5Q24597052-C3E4EB68-C27D-488B-AD2B-F0DEC45170CFQ24615570-9D605D51-7EFB-448F-88C9-48722E0CE34CQ24796311-52F867C3-8CEB-4E94-8B74-4607B56DA995Q24802044-C8BA6DFA-8EE0-4FDC-92FF-E5D4447F9315Q24814633-052A039D-A33B-4AEE-A78D-03F3A6ADF746Q27621483-DD9D2431-8E2B-4EBE-AFF6-9CCBCAA47639Q27622387-0D14FC7D-9C42-4262-9D1C-681DF26C8411Q27677537-F16CAF5E-805F-4C78-BEDF-31AC0E6CEA42Q28081266-BFBD3DC3-1FC7-45FE-A310-70F1EB57A27EQ28389988-F5786E49-BA60-4F8B-B12E-77EC477D9C16Q28469286-5D422493-4DB2-4F82-9205-51808C5D13D1Q28477987-0179CD28-AB1E-4961-899A-2E1F0454CB0EQ28484153-0975C23C-A4EA-45C2-8E1C-0A820FBA4DDCQ28484482-24F106B8-093E-4DB7-AE1E-11059BE595E6Q28484920-8D2CF324-6985-4F00-BD62-1D6121CA5427Q28539369-10A608BA-8128-4AEA-9A10-0EBAD74A954EQ28545222-C3117B3C-4206-47D8-A380-9909D20B3BA9Q28731034-5E85DF3C-3D1D-4EB7-8929-1718CA025CCCQ30240127-5DDBCD18-7579-48A8-9EE4-96D6B007E674Q30336184-BD56A0FF-EDEE-4183-AB6A-F6E05203A0D3Q30352010-0AB54D86-51EF-495E-A1B7-EDF4912D7CA3Q30356074-802776C7-94CC-43FF-BFD2-F618E6D8D5C2Q30421741-BA64EC0E-16AF-49B4-ADF8-3356B03EE687Q30756408-AE9840E9-4D2D-4394-84E2-3A9CC84F6C45Q30849023-EBCD07A3-E463-4DD4-8B3A-19E667C50E17Q31811573-7C33078A-5CAF-48C5-852F-4773B8A2A334Q33298844-AA56078E-3AF7-4E4D-BBFD-2F3715F975E7Q33330114-F3602AEB-C497-44F1-9882-48F1B7A774F7Q33460434-12721AB3-954F-469B-88DB-586F655AECDAQ33486116-BE1BC467-D775-4E7C-98B5-A030659D696CQ33490833-4889FAD9-8428-4617-BA6A-3D9E6A8337D7Q33518011-95D12361-9993-4249-812E-820DD6F56137Q33534648-CEB4219C-4E21-4984-8CA7-F46DDEB4641AQ33573384-68F4EC46-87AA-4702-B997-914C33484EBEQ33595278-CD20D6D5-0D74-40A1-8980-90929755F511
P2860
Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.
description
1998 nî lūn-bûn
@nan
1998 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Changing patterns of mortality ...... h HIV-1. EuroSIDA Study Group.
@ast
Changing patterns of mortality ...... h HIV-1. EuroSIDA Study Group.
@en
Changing patterns of mortality ...... h HIV-1. EuroSIDA Study Group.
@nl
type
label
Changing patterns of mortality ...... h HIV-1. EuroSIDA Study Group.
@ast
Changing patterns of mortality ...... h HIV-1. EuroSIDA Study Group.
@en
Changing patterns of mortality ...... h HIV-1. EuroSIDA Study Group.
@nl
prefLabel
Changing patterns of mortality ...... h HIV-1. EuroSIDA Study Group.
@ast
Changing patterns of mortality ...... h HIV-1. EuroSIDA Study Group.
@en
Changing patterns of mortality ...... h HIV-1. EuroSIDA Study Group.
@nl
P2093
P1433
P1476
Changing patterns of mortality ...... th HIV-1. EuroSIDA Study Group
@en
P2093
A N Phillips
A d'Arminio Monforte
J D Lundgren
P Gargalianos
T L Benfield
P304
P356
10.1016/S0140-6736(98)03201-2
P407
P577
1998-11-01T00:00:00Z